Head to Head Analysis: Celcuity (CELC) and InVitae (NVTA)
Celcuity (NASDAQ:CELC) and InVitae (NYSE:NVTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.
This is a breakdown of recent ratings for Celcuity and InVitae, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility and Risk
Celcuity has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, InVitae has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
Insider & Institutional Ownership
15.2% of Celcuity shares are owned by institutional investors. Comparatively, 75.1% of InVitae shares are owned by institutional investors. 43.5% of Celcuity shares are owned by company insiders. Comparatively, 8.7% of InVitae shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Celcuity and InVitae’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Celcuity and InVitae’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|InVitae||$68.22 million||13.51||-$123.38 million||($2.65)||-4.66|
Celcuity has higher earnings, but lower revenue than InVitae. Celcuity is trading at a lower price-to-earnings ratio than InVitae, indicating that it is currently the more affordable of the two stocks.
Celcuity beats InVitae on 8 of the 12 factors compared between the two stocks.
Celcuity Company Profile
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.